Incidence of post-COVID syndrome and associated symptoms in outpatient care in Bavaria, Germany: a retrospective cohort study using routinely collected claims data.
Epidemiology
General medicine (see Internal Medicine)
Infectious diseases
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
22 09 2022
22 09 2022
Historique:
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
To estimate the treatment incidence of post-COVID syndrome (postinfectious sequelae present at least 12 weeks following infection) in the context of ambulatory care in Bavaria, Germany, and to establish whether related diagnoses occur more frequently than in patients with no known history of COVID-19. Retrospective cohort analysis of routinely collected claims data. Ambulatory care in Bavaria, Germany, observed from January 2020 to March 2022 (data accessed May 2022). 391 990 patients with confirmed COVID-19 diagnosis, 62 659 patients with other respiratory infection and a control group of 659 579 patients with no confirmed or suspected diagnosis of COVID-19. Primary outcome is diagnosis of post-COVID syndrome documented in ambulatory care. Secondary outcomes are: chronic fatigue syndrome, psychological disorder, fatigue, mild cognitive impairment, disturbances of taste and smell, dyspnoea, pulmonary embolism and myalgia. Among all patients with confirmed COVID-19, 14.2% (95% CI 14.0% to 14.5%) received a diagnosis of a post-COVID syndrome, and 6.7% (95% CI 6.5% to 6.9%) received the diagnosis in at least two quarterly periods during a 2-year follow-up. Compared with patients with other respiratory infections and with controls, patients with COVID-19 more frequently received a variety of diagnoses including chronic fatigue syndrome (1.6% vs 0.6% and 0.3%, respectively), fatigue (13.3% vs 9.2% and 6.0%), dyspnoea (9.9% vs 5.1% and 3.2%) and disturbances of taste and smell (3.2% vs 1.2% and 0.5%). The treatment incidence of post-COVID syndrome was highest among adults aged 40-59 (19.0%) and lowest among children aged below 12 years (2.6%). Our results demonstrate a moderately high incidence of post-COVID syndrome 2 years after COVID-19 diagnosis. There is an urgent need to find efficient and effective solutions to help patients with dyspnoea, fatigue, cognitive impairment and loss of smell. Guidelines and treatment algorithms, including referral criteria, and occupational and physical therapy, require prompt and coherent implementation.
Identifiants
pubmed: 36137635
pii: bmjopen-2022-064979
doi: 10.1136/bmjopen-2022-064979
pmc: PMC9511014
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e064979Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: ED, MT and RG are employees of the Association of Statutory Health Insurance Physicians of Bavaria. AS received fees from the Association of Statutory Health Insurance Physicians of Bavaria for lectures on post-COVID syndrome.
Références
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Health Policy. 2013 Mar;109(3):253-62
pubmed: 23276484
Dtsch Arztebl Int. 2022 Mar 11;119(10):175-176
pubmed: 35583039
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
J Rehabil Med. 2021 Jan 5;53(1):jrm00141
pubmed: 33284353
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
Dtsch Arztebl Int. 2022 Apr 8;119(14):261-262
pubmed: 35794803
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Dtsch Arztebl Int. 2021 Jun 25;118(25):425-431
pubmed: 34374332
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487
pubmed: 34870392
Respiration. 2022;101(6):593-601
pubmed: 35203084
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
Pneumologie. 2021 Nov;75(11):869-900
pubmed: 34474488
Gut. 2018 Jun;67(6):1078-1086
pubmed: 28601847
Chron Respir Dis. 2021 Jan-Dec;18:14799731211015691
pubmed: 33957805
Gesundheitswesen. 2015 Feb;77(2):120-6
pubmed: 25622207
J Adv Res. 2022 Sep;40:179-196
pubmed: 36100326
Dtsch Arztebl Int. 2022 Mar 11;119(10):167-174
pubmed: 35236547
Cochrane Database Syst Rev. 2022 Sep 5;9:CD013876
pubmed: 36062970
Disabil Rehabil. 2022 Aug 18;:1-7
pubmed: 35980383
Dtsch Arztebl Int. 2019 Aug 9;116(33-34):553-560
pubmed: 31554544
J Infect Dis. 2022 Apr 16;:
pubmed: 35429399
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Br J Gen Pract. 2021 Oct 28;71(712):e806-e814
pubmed: 34340970